NAD+
NAD+ is one of the most widely referenced molecules in cellular-aging research — a coenzyme whose declining levels with age have made it a central target for interventions aimed at mitochondrial energy production and sirtuin activation.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, central to the electron transport chain that produces cellular energy (ATP) and to activating the sirtuin family of proteins linked to cellular stress resistance and aging research. NAD+ levels are well documented to decline with age, which has made restoring or maintaining them a major focus of longevity research — both through direct NAD+ administration and through precursor molecules the body converts into NAD+.
Research Focus
NAD+ research sits alongside the telomerase/pineal-signaling research behind Epitalon and the mitochondrial membrane research behind SS-31 as one of the major branches of KYIN's Longevity & Cellular Health category, though NAD+ approaches cellular aging from the angle of core energy metabolism rather than telomere maintenance or mitochondrial membrane stability specifically. See our Longevity & Cellular Health research overview for how it fits alongside KYIN's stocked longevity-focused peptides.
Clinical & Preclinical Trial Data
Human trial data for NAD+ comes from studies of its precursor molecules rather than NAD+ administered directly by injection. The first human trial of a NAD+ precursor (Airhart et al., PLOS One, 2017; 12 healthy adults, crossover design) found that single oral doses of nicotinamide riboside (100mg, 300mg, and 1g) raised blood NAD+ by roughly 30% at the lowest dose and up to 50% at the higher doses, establishing precursor supplementation as a viable route to raising NAD+ in humans. A later 12-week randomized, double-blind, placebo-controlled trial (Igarashi et al., npj Aging, 2022) gave 250mg/day of NMN to healthy older men and found nominal improvements in gait speed and grip strength versus placebo, though the authors noted the effect sizes were modest and require replication in larger cohorts. No trial has administered NAD+ itself by injection to a comparable evidence standard.
Availability
NAD+ is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
NAD+ questions
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial energy production and sirtuin activation, studied for its declining levels with age and its potential role in cellular aging research.
Has NAD+ been tested in human trials?
Human trials have tested NAD+ precursors, not NAD+ itself by injection. A 2017 crossover trial found single oral doses of nicotinamide riboside raised blood NAD+ by roughly 30–50% depending on dose. A 2022 trial gave NMN to healthy older men and found nominal improvements in gait speed and grip strength versus placebo, though the authors noted modest effect sizes requiring replication.
Does KYIN Peptides sell NAD+?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing NAD+?
Contact us and we'll help you source it, or browse our stocked longevity-focused peptides.